Starting this year, certain individuals with Medicare can obtain select GLP-1 medications for weight management at a monthly copay of $50. However, this benefit does not extend to all beneficiaries or every drug within this category.
The initiative, known as the Medicare GLP-1 Bridge, was launched on July 1, 2026. The Centers for Medicare & Medicaid Services (CMS) administers it as a temporary program for those with Part D drug coverage who meet specific medical criteria.
According to official Medicare data, the program currently includes Foundayo, Wegovy, and certain forms of Zepbound. This initiative is set to run until December 31, 2027.
Available GLP-1 Medications
Medicare has identified three drugs accessible through the GLP-1 Bridge for those needing to lose or maintain weight:
- Foundayo: available in tablet form.
- Wegovy: offered as an injection or tablet.
- Zepbound: limited to the KwikPen version.
It's important to note that for Zepbound, Medicare does not cover vials or single-dose pens.
The list of covered medications may change, so it is advisable to regularly check Medicare’s official page on weight loss medications before starting the process.
Cost and Payment Details
Eligible beneficiaries pay a $50 copay at the pharmacy for a 28- or 30-day supply, depending on the medication. This amount is unaffected by the beneficiary's income level.
Unlike typical Part D medications, the GLP-1 Bridge operates independently from the standard Part D payment system. This means the $50:
- Does not apply towards the annual drug plan deductible.
- Is not counted towards the Part D annual out-of-pocket maximum.
- Cannot be reduced through Medicare’s Extra Help program.
- Cannot be spread over multiple months through the Medicare Prescription Payment Plan.
Moreover, CMS specifies that coupons and certain discount programs cannot be used to lower the GLP-1 Bridge copay.
Eligibility Criteria
To access the program, individuals must have Medicare Part D drug coverage, which can be through a standalone drug plan or specific Medicare Advantage plans that include drug coverage.
Additionally, certain clinical criteria must be met. Medicare outlines three primary eligibility pathways for adults aged 18 and older:
- Having a body mass index (BMI) of 35 or higher, with no additional medical conditions required.
- A BMI of 30 or above plus at least one of the following conditions: heart failure with preserved ejection fraction, hard-to-control hypertension, or stage 3a chronic kidney disease or higher.
- A BMI of 27 or above and at least one of the following: prediabetes, a previous heart attack, a past stroke, or symptomatic peripheral arterial disease.
The BMI must be evaluated when starting GLP-1 treatment.
Exclusions and Additional Information
The GLP-1 Bridge is primarily designed to increase access to these medications for weight control. It is not available to those already receiving a GLP-1 covered by their Medicare drug plan.
Medicare advises those with type 2 diabetes, moderate to severe obstructive sleep apnea, or certain liver diseases to explore coverage through their standard Part D plan for these conditions, rather than using the GLP-1 Bridge.
The CMS aims to prevent the misallocation of medications already covered by Part D for medical indications from being shifted to the $50 special program.
Application Process
The process does not begin with an independent application to Medicare. Individuals who believe they meet the requirements should first consult with their healthcare provider to determine if one of these medications is suitable for their situation.
If applicable, the healthcare professional will send the prescription to the pharmacy and complete any necessary prior authorization to verify that the patient meets the program criteria.
Medicare also requires the provider to certify that the patient is using the medication as part of a lifestyle program that includes diet and exercise.
Program Duration and Changes
Once prior authorization is approved, beneficiaries are notified by Medicare that the medication is covered under the GLP-1 Bridge. This authorization can remain valid, including refills and dosage changes, until December 31, 2027, unless the patient switches to a different GLP-1 medication, which may necessitate a new authorization.
If a beneficiary is already taking a GLP-1, they may still access the program, depending on how the medication is currently being paid for. If the GLP-1 is already covered by their Medicare drug plan, the GLP-1 Bridge cannot be used to switch to the $50 copay.
For those paying for the medication through other means and meeting the GLP-1 Bridge criteria, consulting a healthcare provider and verifying eligibility with Medicare is recommended.
Nationwide Availability
The Medicare GLP-1 Bridge is accessible in all U.S. states and territories for qualifying individuals. Beneficiaries can use the tool on Medicare.gov to preliminarily check eligibility or contact 1-800-MEDICARE (1-800-633-4227) for questions about eligibility or the status of a prior authorization.
As beneficiaries begin reviewing options for the upcoming year, it is crucial not to confuse the GLP-1 Bridge with regular drug coverage. Medicare now allows comparisons of available plans for 2027 before the Open Enrollment period begins on October 15.
While comparing plans, it remains important to check which drugs are directly covered by each Part D option, along with their prior authorization requirements, deductibles, and copays. The GLP-1 Bridge is a separate, temporary program specifically for eligible beneficiaries needing these treatments for weight management, as outlined by CMS.
Consider these questions to determine if consulting a healthcare provider is worthwhile:
- Do you currently have Medicare Part D drug coverage?
- Is your GLP-1 medication not already covered by that Part D?
- Do you meet any of the BMI and medical condition criteria established by Medicare?
- Is the medication being used for weight loss or maintenance?
If the answers suggest potential eligibility, the next step is to consult a healthcare professional and use the official Medicare tool. The $50 copay exists, but it is not automatic coverage for anyone with Medicare or any GLP-1 prescription.
Understanding the Medicare GLP-1 Bridge Program
What is the Medicare GLP-1 Bridge?
The Medicare GLP-1 Bridge is a temporary program allowing certain Medicare beneficiaries to access select GLP-1 medications for weight management at a $50 monthly copay, provided they meet specific eligibility criteria.
Who qualifies for the GLP-1 Bridge?
Eligibility is determined by having Medicare Part D coverage and meeting specific clinical criteria, such as certain BMI thresholds and related medical conditions.
How do I apply for the Medicare GLP-1 Bridge?
The application process begins by consulting with a healthcare provider to determine suitability. If eligible, the provider will handle the prescription and any necessary authorizations.
What medications are covered under the GLP-1 Bridge?
The program currently includes Foundayo, Wegovy, and specific forms of Zepbound, although the list is subject to change.